A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

NCT05877547 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
NAFLD
Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis

Interventions

DRUG: Efinopegdutide
DRUG: Semaglutide
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC